ATE547416T1 - Pyrazolylbenzothiazolderivate und deren verwendung als therapeutische mittel - Google Patents
Pyrazolylbenzothiazolderivate und deren verwendung als therapeutische mittelInfo
- Publication number
- ATE547416T1 ATE547416T1 AT03771002T AT03771002T ATE547416T1 AT E547416 T1 ATE547416 T1 AT E547416T1 AT 03771002 T AT03771002 T AT 03771002T AT 03771002 T AT03771002 T AT 03771002T AT E547416 T1 ATE547416 T1 AT E547416T1
- Authority
- AT
- Austria
- Prior art keywords
- pyrazolylbenzothiazole
- derivatives
- therapeutic agents
- topical
- derivative
- Prior art date
Links
- YAMYGQRUEXYQIE-UHFFFAOYSA-N 2-(1h-pyrazol-5-yl)-1,3-benzothiazole Chemical class N1N=CC=C1C1=NC2=CC=CC=C2S1 YAMYGQRUEXYQIE-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- 239000012049 topical pharmaceutical composition Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39850402P | 2002-07-24 | 2002-07-24 | |
| PCT/CA2003/001078 WO2004011460A2 (en) | 2002-07-24 | 2003-07-23 | Pyrazolylbenzothiazole derivatives and their use as therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE547416T1 true ATE547416T1 (de) | 2012-03-15 |
Family
ID=31188411
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03771002T ATE547416T1 (de) | 2002-07-24 | 2003-07-23 | Pyrazolylbenzothiazolderivate und deren verwendung als therapeutische mittel |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US7847101B2 (de) |
| EP (1) | EP1542997B1 (de) |
| JP (2) | JP4468810B2 (de) |
| AT (1) | ATE547416T1 (de) |
| AU (1) | AU2003254650B2 (de) |
| CA (1) | CA2492964C (de) |
| DK (1) | DK1542997T3 (de) |
| ES (1) | ES2385378T3 (de) |
| WO (1) | WO2004011460A2 (de) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1542997B1 (de) | 2002-07-24 | 2012-02-29 | Dermira (Canada), Inc. | Pyrazolylbenzothiazolderivate und deren verwendung als therapeutische mittel |
| AU2004303602C1 (en) | 2003-12-23 | 2009-05-28 | Astex Therapeutics Limited | Pyrazole derivatives as protein kinase modulators |
| US8343953B2 (en) | 2005-06-22 | 2013-01-01 | Astex Therapeutics Limited | Pharmaceutical compounds |
| US8541461B2 (en) | 2005-06-23 | 2013-09-24 | Astex Therapeutics Limited | Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators |
| JP2009501164A (ja) * | 2005-07-15 | 2009-01-15 | ４エスツェー アクチェンゲゼルシャフト | ２−アリールベンゾチアゾール及びその使用 |
| EP2468752A1 (de) * | 2005-08-04 | 2012-06-27 | Sirtris Pharmaceuticals, Inc. | Thiazolopyridin-Derivate als Sirtuin-Modulatoren |
| EP1934185A1 (de) | 2005-08-12 | 2008-06-25 | Synta Pharmaceuticals Corporation | Die hsp90-aktivität modulierenden pyrazolverbindungen |
| GB0704932D0 (en) | 2007-03-14 | 2007-04-25 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| TW200911240A (en) * | 2007-06-11 | 2009-03-16 | Kyowa Hakko Kogyo Kk | Anti-tumor agent |
| TW200916472A (en) | 2007-06-20 | 2009-04-16 | Sirtris Pharmaceuticals Inc | Sirtuin modulating compounds |
| CN102036982A (zh) * | 2008-05-21 | 2011-04-27 | 巴斯夫欧洲公司 | 作为杀真菌剂的取代吡啶-4-基甲基磺酰胺 |
| DK2789684T3 (en) | 2008-05-23 | 2017-02-20 | Siwa Corp | Methods and compositions for facilitating regeneration |
| US8731655B2 (en) | 2009-05-12 | 2014-05-20 | Mallinckrodt Llc | Compounds containing acyclic N-N bonds for phototherapy |
| WO2010132554A2 (en) | 2009-05-12 | 2010-11-18 | Mallinckrodt Inc. | Diaza heterocyclic compounds for phototherapy |
| BR112012000254A2 (pt) | 2009-07-08 | 2016-02-16 | Dermira Canada Inc | análogos de tofa úteis no tratamento de distúrbios ou condições dermatológicas. |
| US9649376B2 (en) | 2010-09-27 | 2017-05-16 | Siwa Corporation | Selective removal of age-modified cells for treatment of atherosclerosis |
| US8721571B2 (en) | 2010-11-22 | 2014-05-13 | Siwa Corporation | Selective removal of cells having accumulated agents |
| WO2012071310A1 (en) | 2010-11-24 | 2012-05-31 | The Ohio State University Research Foundation | Integrin-linked kinase inhibitors |
| AU2011337565A1 (en) * | 2010-11-30 | 2013-07-11 | Takeda Pharmaceutical Company Limited | Bicyclic compound |
| LT6064B (lt) | 2012-10-15 | 2014-08-25 | Vilniaus Universitetas | Fluorinti benzensulfonamidai kaip karboanhidrazės inhibitoriai |
| CN102875541A (zh) * | 2012-11-02 | 2013-01-16 | 天津希恩思生化科技有限公司 | 3-(2-苯并恶唑基)-7-羟基香豆素的制备方法 |
| CN102875486A (zh) * | 2012-11-02 | 2013-01-16 | 天津希恩思生化科技有限公司 | 2-苯并恶唑乙腈的制备方法 |
| ITMI20132192A1 (it) * | 2013-12-23 | 2015-06-24 | Purisa S R L | Composti antimicrobici |
| JP2017513812A (ja) * | 2014-02-28 | 2017-06-01 | ザ ロイヤル インスティチューション フォー ジ アドヴァンスメント オブ ラーニング／マギル ユニヴァーシティ | 免疫療法用のａｐｃ活性剤としてのｔｃ−ｐｔｐ阻害剤 |
| CN107001459B (zh) | 2014-09-19 | 2021-11-23 | Siwa有限公司 | 用于治疗炎症和自身免疫紊乱的抗age抗体 |
| US9993535B2 (en) | 2014-12-18 | 2018-06-12 | Siwa Corporation | Method and composition for treating sarcopenia |
| US10358502B2 (en) | 2014-12-18 | 2019-07-23 | Siwa Corporation | Product and method for treating sarcopenia |
| WO2018191718A1 (en) | 2017-04-13 | 2018-10-18 | Siwa Corporation | Humanized monoclonal advanced glycation end-product antibody |
| ES2912064T3 (es) | 2016-02-19 | 2022-05-24 | Siwa Corp | Método y composición para tratar el cáncer, destruir las células cancerosas metastásicas y evitar la metástasis del cáncer usando anticuerpo para productos finales de glicación avanzada (AGE) |
| KR20180133452A (ko) | 2016-04-15 | 2018-12-14 | 시와 코퍼레이션 | 신경퇴행성 질환을 치료하기 위한 항-노화 항체 |
| JP2019518763A (ja) | 2016-06-23 | 2019-07-04 | シワ コーポレーション | 様々な疾患及び障害の治療において使用するためのワクチン |
| GB201617339D0 (en) * | 2016-10-12 | 2016-11-23 | Lytix Biopharma As | Therapeutic compounds |
| US10995151B1 (en) | 2017-01-06 | 2021-05-04 | Siwa Corporation | Methods and compositions for treating disease-related cachexia |
| US10925937B1 (en) | 2017-01-06 | 2021-02-23 | Siwa Corporation | Vaccines for use in treating juvenile disorders associated with inflammation |
| US10858449B1 (en) | 2017-01-06 | 2020-12-08 | Siwa Corporation | Methods and compositions for treating osteoarthritis |
| US10961321B1 (en) | 2017-01-06 | 2021-03-30 | Siwa Corporation | Methods and compositions for treating pain associated with inflammation |
| US11518801B1 (en) | 2017-12-22 | 2022-12-06 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
| US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| AU2020209144A1 (en) * | 2019-01-18 | 2021-07-29 | Vtv Therapeutics Llc | Substituted fused imidazole derivatives and methods of treating sickle cell disease and related complications |
| CN111559989B (zh) * | 2020-04-12 | 2022-09-09 | 青岛科技大学 | 一种可见光促进2-氨基萘并[2,1-d]噻唑类化合物的合成方法和应用 |
| WO2024003408A1 (en) * | 2022-07-01 | 2024-01-04 | Universität Zürich | Small-molecule inhibitors of the frs2-fgfr interaction |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS52108427A (en) | 1976-03-10 | 1977-09-10 | Hodogaya Chem Co Ltd | Solubilization of dyes into aromatic hydrocarbon solvent |
| US4269846A (en) * | 1979-10-29 | 1981-05-26 | Usv Pharmaceutical Corporation | Heterocyclic compounds useful as anti-allergy agents |
| US5770592A (en) | 1991-11-22 | 1998-06-23 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization using angiostatic steroids |
| US5798349A (en) | 1994-03-14 | 1998-08-25 | The General Hospital Corporation | Use of green porphyrins to treat neovasculature in the eye |
| JP2961074B2 (ja) | 1995-09-06 | 1999-10-12 | 明治製菓株式会社 | 光化学療法用の新生血管閉塞剤 |
| US6043237A (en) | 1996-12-10 | 2000-03-28 | Qlt Phototherapeutics, Inc. | Use of photodynamic therapy for prevention of secondary cataracts |
| US6136831A (en) * | 1997-04-11 | 2000-10-24 | Grelan Pharmaceutical Co., Ltd. | Pyrazole derivatives and COX inhibitors containing them |
| US6214819B1 (en) | 1998-11-23 | 2001-04-10 | Novartis Ag | Method for treating ocular neovascular diseases |
| US6217895B1 (en) | 1999-03-22 | 2001-04-17 | Control Delivery Systems | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
| US6271233B1 (en) | 1999-08-10 | 2001-08-07 | Ciba Vision Corporation | Method for treating ocular neovascular diseases |
| WO2001053331A2 (en) * | 2000-01-24 | 2001-07-26 | Adherex Technologies, Inc. | Peptidomimetic modulators of cell adhesion |
| US6436915B1 (en) | 2000-04-07 | 2002-08-20 | Kinetek Pharmaceuticals, Inc. | Pyrazole compounds |
| GB0102687D0 (en) | 2001-02-02 | 2001-03-21 | Pharmacia & Upjohn Spa | Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them |
| NZ532816A (en) * | 2001-11-09 | 2005-11-25 | Cv Therapeutics Inc | A2B adenosine receptor antagonists |
| AU2002356301A1 (en) * | 2001-12-21 | 2003-07-15 | Cancer Research Technology Ltd. | 3,4-diarylpyrazoles and their use in the therapy of cancer |
| GB0206860D0 (en) * | 2002-03-22 | 2002-05-01 | Glaxo Group Ltd | Compounds |
| EP1542997B1 (de) * | 2002-07-24 | 2012-02-29 | Dermira (Canada), Inc. | Pyrazolylbenzothiazolderivate und deren verwendung als therapeutische mittel |
-
2003
- 2003-07-23 EP EP03771002A patent/EP1542997B1/de not_active Expired - Lifetime
- 2003-07-23 US US10/521,948 patent/US7847101B2/en not_active Expired - Fee Related
- 2003-07-23 AT AT03771002T patent/ATE547416T1/de active
- 2003-07-23 DK DK03771002.7T patent/DK1542997T3/da active
- 2003-07-23 WO PCT/CA2003/001078 patent/WO2004011460A2/en active Application Filing
- 2003-07-23 ES ES03771002T patent/ES2385378T3/es not_active Expired - Lifetime
- 2003-07-23 JP JP2004523674A patent/JP4468810B2/ja not_active Expired - Fee Related
- 2003-07-23 AU AU2003254650A patent/AU2003254650B2/en not_active Expired - Fee Related
- 2003-07-23 CA CA2492964A patent/CA2492964C/en not_active Expired - Fee Related
-
2010
- 2010-01-04 JP JP2010000195A patent/JP5405326B2/ja not_active Expired - Fee Related
- 2010-10-22 US US12/910,744 patent/US8410272B2/en not_active Expired - Fee Related
-
2013
- 2013-02-25 US US13/776,503 patent/US8754233B2/en not_active Expired - Fee Related
-
2014
- 2014-05-06 US US14/271,263 patent/US9434720B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20110178126A1 (en) | 2011-07-21 |
| DK1542997T3 (da) | 2012-06-25 |
| WO2004011460A3 (en) | 2004-05-06 |
| JP5405326B2 (ja) | 2014-02-05 |
| AU2003254650B2 (en) | 2010-09-09 |
| EP1542997A2 (de) | 2005-06-22 |
| EP1542997B1 (de) | 2012-02-29 |
| US20130237572A1 (en) | 2013-09-12 |
| US8410272B2 (en) | 2013-04-02 |
| US8754233B2 (en) | 2014-06-17 |
| JP4468810B2 (ja) | 2010-05-26 |
| US20140350009A1 (en) | 2014-11-27 |
| US9434720B2 (en) | 2016-09-06 |
| CA2492964C (en) | 2012-07-17 |
| JP2006505512A (ja) | 2006-02-16 |
| AU2003254650A1 (en) | 2004-02-16 |
| US7847101B2 (en) | 2010-12-07 |
| CA2492964A1 (en) | 2004-02-05 |
| ES2385378T3 (es) | 2012-07-24 |
| WO2004011460A2 (en) | 2004-02-05 |
| US20060247210A1 (en) | 2006-11-02 |
| JP2010111691A (ja) | 2010-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE547416T1 (de) | Pyrazolylbenzothiazolderivate und deren verwendung als therapeutische mittel | |
| ATE555789T1 (de) | Pyridazinderivate und deren verwendung als therapeutische mittel | |
| ATE532772T1 (de) | Piperazinderivate und deren verwendung als therapeutische mittel | |
| DE60335911D1 (de) | Isochinolinonderivate und deren verwendung als medikamente | |
| DK1288205T3 (da) | Nye phenylalanin-derivater | |
| DK0734383T3 (da) | Cykliske amidderivater som neurokinin-A-antagonister | |
| SE0104250D0 (sv) | Heterocyclic compounds | |
| SE0300908D0 (sv) | Azaindole derivatives, preparations thereof, uses thereof and compositions containing them | |
| DE60139382D1 (de) | 2-hydroxy-mutilin-carbamat derivate und ihre anwendung als antibakterielle mittel | |
| DE69910799D1 (de) | Als inhibitoren der aicarftnützliche verbindungen | |
| BR0309996A (pt) | Composto, composição farmacêutica, método de tratar ou melhorar doenças ou condições proliferativas, uso de um composto, e, método de tratar ou melhorar doenças inflamatórias | |
| SE0300105D0 (sv) | Diarylmethylidene piperdine derivatives, preparations thereof and uses thereof | |
| ATE250610T1 (de) | Kaliumkanal-blockierende mittel | |
| DE69828522D1 (de) | Antithrombotische mittel | |
| TR200001122T2 (tr) | Farmasötikler olarak bifenil türevleri. | |
| SE0301445D0 (sv) | Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof | |
| EP2266566A3 (de) | Nicotinamid Derivate und ihrer Verwendung als Therapeutika | |
| ATE140922T1 (de) | 3- oder 4-glykosyloxybenzopyranderivat und dieses enthaltende antiallergisches mittel | |
| SE0300104D0 (sv) | Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof | |
| SE0301442D0 (sv) | Diarylmethylidene piperidine derivatives, preparations therof and uses thereof | |
| TR200100475T2 (tr) | N-İkameli azabisikloheptan türevlerinin üretimleri ve kullanımları. | |
| ATE258934T1 (de) | Azaindol derivate und ihre verwendung als antithrombotische wirkstoffe | |
| SE0300103D0 (sv) | Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof | |
| CY1107483T1 (el) | Παραγωγα πυριδαζινης, η χρηση τους ως φαρμακευτικα σκευασματα και η διαδικασια παρασκευης τους | |
| NO20055142L (no) | Diarylmetylidenpiperidinderivater, fremstillinger og anvendelser derav |